Khavinson Peptide Bioregulators: Research History vs. FDA Approval

Scientific lineage isn’t the same as regulatory approval.

Products marketed as Khavinson peptide bioregulators are sold in the United States as dietary supplements, and formulations vary. No peptide bioregulator is FDA-approved for any use in the United States, and the published clinical evidence does not currently support recommending them for clinical use.

Interest in Khavinson peptide bioregulators is understandable: they are discussed in connection with tissue-specific signaling and decades of work associated with Vladimir Khavinson. But what does that history establish, and where does it stop? A proposed biological mechanism, use in another country and evidence from well-designed clinical studies are three different things. This guide explains what peptide bioregulators are, how the two Khavinson research approaches differ, and what the evidence does and doesn’t establish, including US regulatory status.

Key takeaways

• A supplement’s regulatory category is not a drug approval. Use in Russia does not establish US approval.
• Judge research by study design, outcomes and independent replication, not by publication counts.
• Organ-derived peptide complexes (Cytomaxes) and synthetic short peptides (cytogens) are different research subjects.
• A described use is a proposed biological role, not proof that a product produces a benefit.

Contents

1. What are peptide bioregulators?
2. Two approaches: Cytomaxes vs. Cytogens
3. Named preparations and how they are described
4. Research history vs. FDA approval: US regulatory status
5. What the evidence does and doesn’t show
6. Pure Fire Nutritional’s bioregulator range
7. Frequently asked questions

What are peptide bioregulators?

In the Khavinson research tradition, peptide bioregulators are short peptides, typically 2 to 4 amino acids long. The hypothesis is that they act as signals within particular tissues rather than as broad, conventional therapies. That tissue-specific idea is still a hypothesis. It does not establish that taking a supplement reliably changes human health.

The proposed mechanism centers on gene expression, the process cells use to read genetic instructions and make functional molecules. Khavinson’s group proposed that short peptides interact with DNA and influence gene expression (Khavinson et al., 2012). That model comes mainly from laboratory and cell studies by the originating group. Mainstream biology has not established it.

For example, Epitalon (also spelled Epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, studied in connection with the pineal gland. A frequently cited cell-culture study reported telomerase activity in human fibroblasts exposed to it (Khavinson, Bondarev & Butyugov, 2003). That is one laboratory finding in cells. It is not evidence of an effect in people.

Related reading: Oral vs. injectable peptide bioregulators: digestion and delivery explains why the route a peptide takes into the body matters before any proposed target is reached.

Two approaches: Cytomaxes vs. Cytogens

Terms used on this page are defined in our glossary of Cytomaxes, Cytogens and A-numbers.

Vladimir Khavinson’s work joined peptide research with bioregulation and gerontology. He directed the Saint Petersburg Institute of Bioregulation and Gerontology. According to the manufacturer’s press kit, Peptides, the company that produces these products and was founded in 2010, became the Institute’s exclusive representative in December 2019 and names Khavinson as its chief scientific consultant. The program’s central distinction is between two kinds of research subjects:

• Cytomaxes (in the research literature, cytamins or cytomedins): complex peptide mixtures isolated from animal tissues. The manufacturer’s press kit describes them as made by a multi-month extraction of peptide fractions. The first approach kept the mixture from the source tissue.
• Cytogens: synthetic short peptides, made from amino acids, intended to represent active sequences identified in those extracts. The manufacturer’s press kit describes each Cytogen as a synthesized copy of the working part of the most active section of the extract’s peptide. In organ-culture experiments, the group reported that synthetic cytogens affected explants from the same tissues whose extracts they were modelled on (Khavinson, 2001).

According to the group’s own accounts, the experimental work began in the 1970s and the synthetic approach followed in the late 1990s. The two are distinct research subjects, not interchangeable formulas, and each named preparation should be assessed on its own evidence.

The group has also reported introducing peptide-based pharmaceuticals and food supplements into use in Russia, and holding a large patent portfolio. Those figures come from the originating group. Patents document inventions, not effectiveness, and use in Russia does not establish US approval or equivalent evidence for every formulation.

Related reading: Bioregulator organ pairings: proposed mechanism vs. measured evidence looks at how organ pairings are assigned and what would count as evidence for them.

Named preparations and how they are described

Named preparations in the literature include Thymalin, Thymogen, Epithalamin, Cortexin and Retinalamin. Each is associated with a particular tissue or system. That framing explains the intended research rationale, not a demonstrated outcome.

• Thymalin: a thymus-derived peptide preparation (a tissue extract) studied in relation to immune function.
• Thymogen: a synthetic dipeptide, L-Glu-L-Trp, that the group isolated from Thymalin and then synthesized (Morozov & Khavinson, 1997). One is a tissue preparation and the other a defined synthetic peptide, though both are associated with immune research.
• Epithalamin: a pineal-gland preparation studied in relation to endocrine regulation and melatonin. Epitalon is the synthetic tetrapeptide associated with it.
• Cortexin: a cerebral-cortex preparation studied in relation to brain function.
• Retinalamin: a retina-derived preparation studied in relation to retinal function.

Thymalin, Epithalamin, Cortexin and Retinalamin are injectable drugs in Russia, and much of the human research on them used injected preparations. Not all of the human work was injected, though. The group also studied oral forms, including Cytomax-type (cytamin) and Cytogen capsules and sublingual preparations. For example, an oral synthetic tetrapeptide (Pancragen) was studied on metabolic markers in a small group of older adults (Korkushko et al., 2011). Because the route changes what reaches the body, oral and injected results should be read separately, not pooled.

Research history vs. FDA approval: US regulatory status

Peptide bioregulators are not FDA-approved drugs in the United States, and none is an established bulk drug substance for 503A pharmacy compounding. Availability as a dietary supplement is not approval as a drug or authorization for medical treatment. Under US rules, dietary supplements are not reviewed by the FDA for safety or effectiveness before they are marketed (FDA: dietary supplements).

The FDA has separately been reviewing certain peptide bulk drug substances for compounding. Some peptides, reportedly including Epitalon, were placed in Category 2 of its interim 503A bulks list and later moved into review. In July 2026 an FDA advisory committee discussed several peptides (Johns Hopkins Bloomberg School of Public Health, 2026). These are procedural steps about compounding. They are not drug approval and do not establish safety or efficacy.

Safety also can’t be inferred from a short sequence, a tissue-specific rationale or a supplement label. The questions to ask are what the product contains, what use is claimed, and whether evidence supports that use.

What the evidence does and doesn’t show

Thymalin and Epithalamin have a long history of clinical use in Russia, and the group has published reviews of its clinical work (Khavinson et al., 2013). A history of use, however, is not the same as evidence of benefit.

Independent replication is limited. Studies commonly have modest sample sizes, biochemical or self-reported outcomes, and variable blinding and randomization. Much of the work is in cells or animals. The human studies include both injected preparations and oral forms, and the oral studies in particular tend to be small, mostly come from the originating group, and often have no comparison group. All of this makes it hard to tell whether observed changes translate into meaningful effects in people. The Short Peptide, an independent reference site, keeps a plain-language guide to this research for readers who want to go further.

Pure Fire Nutritional’s bioregulator range

Pure Fire Nutritional offers oral peptide bioregulator supplements, including Khavinson Cytomaxes, Khavinson Cytogens and Prime peptide bioregulators. They are dietary supplements, not drugs, and are not intended to diagnose, treat, cure or prevent any disease. For background on the category, see What are Khavinson peptide bioregulators? and Peptides in context: a systems view, or browse the Longevity Journal.

If you’re exploring a supplement category, a product description can inform your choice. If you have a health concern, talk to a qualified clinician first.

Frequently asked questions

Do oral bioregulator capsules work?

Current clinical evidence doesn’t establish that oral bioregulator capsules produce their described effects. A capsule format can’t show that ingredients reach a target tissue. Any claim needs evidence tied to the specific preparation, route and outcome.

Is there research on bioregulators?

Yes, much of it from Khavinson’s group in Russia. What matters is what those studies show. A biochemical change, a participant’s report and a measurable health outcome are different things, and controls, blinding, randomization and replication all affect how much weight a finding can bear.

What is the theory behind them?

The hypothesis is that certain short peptides act as signals in particular tissues and influence gene expression there. It is a proposed mechanism. A plausible explanation does not, by itself, show that an oral product benefits people.

Why isn’t Khavinson’s research more widely cited in Western medicine?

Findings shape practice when others can assess and reproduce them. Independent replication of this work is limited, and methods and outcomes vary, so the findings are harder to bring into evidence-based practice.

Who was Vladimir Khavinson?

Vladimir Khavinson was a Russian gerontologist whose work focused on peptide bioregulation and aging. “Peptide bioregulators” names a research approach, not a single substance with a uniform effect.